NASDAQ:SILO Silo Pharma (SILO) Stock Price, News & Analysis $0.68 -0.02 (-2.49%) As of 11:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Silo Pharma Stock (NASDAQ:SILO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Silo Pharma alerts:Sign Up Key Stats Today's Range$0.67▼$0.6950-Day Range$0.43▼$0.6952-Week Range$0.41▼$3.37Volume81,453 shsAverage Volume1.85 million shsMarket Capitalization$3.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida. Read More Silo Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreSILO MarketRank™: Silo Pharma scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Silo Pharma. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Silo Pharma is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Silo Pharma is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSilo Pharma has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Silo Pharma's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.66% of the float of Silo Pharma has been sold short.Short Interest Ratio / Days to CoverSilo Pharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silo Pharma has recently decreased by 56.89%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSilo Pharma does not currently pay a dividend.Dividend GrowthSilo Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.66% of the float of Silo Pharma has been sold short.Short Interest Ratio / Days to CoverSilo Pharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silo Pharma has recently decreased by 56.89%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 3 people have searched for SILO on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Silo Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,300.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.37% of the stock of Silo Pharma is held by insiders.Percentage Held by InstitutionsOnly 5.58% of the stock of Silo Pharma is held by institutions.Read more about Silo Pharma's insider trading history. Receive SILO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silo Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address SILO Stock News HeadlinesSilo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15July 16, 2025 | globenewswire.comSilo Pharma (NASDAQ:SILO) Raised to "Sell" at Wall Street ZenJuly 14, 2025 | americanbankingnews.comTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trillions in oil, gas, lithium, and land rights. Whitney Tilson breaks it all down, and shows how everyday Americans can grab a stake. His urgent new briefing explains "The US: IPO"... and how to get in before the looming federal deadline.July 24 at 2:00 AM | Stansberry Research (Ad)Silo Pharma Secures Exclusive License for CNS PeptidesJuly 10, 2025 | tipranks.comSilo Pharma, Inc. Plans IND Application Submission for PTSD Drug SPC-15 with Potential Phase 1 Trial in 2026 - NasdaqJuly 9, 2025 | nasdaq.comSilo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025July 7, 2025 | globenewswire.comSilo Pharma Faces Nasdaq Non-Compliance NoticeJuly 3, 2025 | msn.comSilo Pharma and Hoth Therapeutics plan joint venture for obesity treatmentJune 26, 2025 | investing.comSee More Headlines SILO Stock Analysis - Frequently Asked Questions How have SILO shares performed this year? Silo Pharma's stock was trading at $0.89 at the beginning of the year. Since then, SILO stock has decreased by 23.9% and is now trading at $0.6770. How were Silo Pharma's earnings last quarter? Silo Pharma, Inc. (NASDAQ:SILO) released its earnings results on Friday, May, 9th. The company reported ($0.23) EPS for the quarter. The company had revenue of $0.02 million for the quarter. Silo Pharma had a negative net margin of 6,420.83% and a negative trailing twelve-month return on equity of 84.88%. How do I buy shares of Silo Pharma? Shares of SILO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Silo Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Silo Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Citius Pharmaceuticals (CTXR), Sunshine Biopharma (SBFM), AbbVie (ABBV) and Biorestorative Therapies (BRTX). Company Calendar Last Earnings5/09/2025Today7/24/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryApparel Current SymbolNASDAQ:SILO CIK1514183 Websilopharma.com Phone(718) 400-9031FaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.39 million Net Margins-6,420.83% Pretax Margin-6,419.44% Return on Equity-84.88% Return on Assets-61.81% Debt Debt-to-Equity RatioN/A Current Ratio4.73 Quick Ratio4.73 Sales & Book Value Annual Sales$70 thousand Price / Sales44.44 Cash FlowN/A Price / Cash FlowN/A Book Value$1.12 per share Price / Book0.62Miscellaneous Outstanding Shares4,480,000Free Float4,288,000Market Cap$3.11 million OptionableNot Optionable Beta0.29 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:SILO) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silo Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silo Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.